Welcome to LookChem.com Sign In|Join Free
  • or

1032900-25-6

Post Buying Request

1032900-25-6 Suppliers

Recommended suppliersmore

Product FOB Price Min.Order Supply Ability Supplier
Ceritinib/1032900-25-6/ 50Kgs in stock
Cas No: 1032900-25-6
USD $ 1000.0-1000.0 / Gram 1 Gram 1000 Gram/Day Shenzhen Tianyuan Pharmaceutical Technology Co., Ltd Contact Supplier
Ceritinib (LDK378) 1032900-25-6
Cas No: 1032900-25-6
USD $ 15.0-15.0 / Gram 100 Gram 1000 Gram/Week Wuhan Ying Yuan Bei Biological Limited Contact Supplier
Ceritinib
Cas No: 1032900-25-6
USD $ 100.0-100.0 / Gram 1 Gram 100 Kilogram/Month coolpharm Ltd Contact Supplier
Ceritinib
Cas No: 1032900-25-6
USD $ 3.0-3.0 / Kilogram 1 Kilogram 1-100 Metric Ton/Month Hangzhou Dayangchem Co., Ltd. Contact Supplier
ceritinib
Cas No: 1032900-25-6
No Data 1 Kilogram 10 Metric Ton/Month Hebei yanxi chemical co.,LTD. Contact Supplier
High purity Various Specifications Ceritinib CAS:1032900-25-6
Cas No: 1032900-25-6
USD $ 100.0-500.0 / Gram 1 Gram 99999 Gram/Year Hangzhou Dingyan Chem Co., Ltd Contact Supplier
Ceritinib;LDK 378
Cas No: 1032900-25-6
No Data 1 Kilogram 20 Metric Ton/Month Henan Allgreen Chemical Co.,Ltd Contact Supplier
High quality LDK378 supplier in China
Cas No: 1032900-25-6
No Data No Data No Data Simagchem Corporation Contact Supplier
Ceritinib
Cas No: 1032900-25-6
No Data 1 Gram Metric Ton/Day Shenzhen READLINE Technology Co., Ltd. Contact Supplier
Ceritinib dihydrochloride
Cas No: 1032900-25-6
No Data No Data No Data Chemwill Asia Co., Ltd. Contact Supplier

1032900-25-6 Usage

Indications and Usage

Ceritinib is a new ALK gene inhibitor (ALKi) developed by Novartis Pharmaceuticals; its commercial name is Zykadia, and its previous code was LDK378. It was approved by the FDA for sale on April 29, 2014, and it is used to treat anaplastic lymphoma kinase (ALK) positive transfer of crizotinib (CRZ) progress or intolerance of non-small cell lung cancer (NSCLC).

Mechanisms of Action

Crizotinib resistance is a major issue for patients undergoing treatment for ALK gene rearrangement positive non-small cell lung cancer. Ceritinib is a kind of ALK tyrosine kinase inhibitor. Ceritinib does not target the MET proto-oncogene, but instead inhibits the insulin-like growth factor 1 receptor and blocks proteins from promoting cancer cell development, thus inhibiting the expression of EML4-ALK and NPM-ALK fusion protein cells. It is used to treat ALK rearrangement positive NSCLC patients who have previously used Crizotinib and can overcome Crizotinib resistance. Compared to Crizotinib, Ceritinib does not inhibit MET kinase activity, but inhibits IGF-1 receptors. Whether in terms of enzyme reaction, cell analysis or Crizotinib resistant animal models, research results all show that Ceritinib is more effective than Crizotinib. Additionally, regardless of any ALK resistance mutation, Ceritinib is still highly effective. In clinical models, Ceritinib’s ALK inhibition has 20 times the tumor-fighting effect of Crizotinib. Ceritinib also has the same effect on Crizotinib resistant central nervous system lesion NSCLC. Clinical trials show that Ceritinib can effectively inhibit ALK targets, potentially affecting an unknown kinase related to drug resistance, thus overcoming Crizotinib resistance.

Patents

American patent numbers: US7153964,US7893074,US7964592,US8039474,US8039479,US8377921,US8703787.
Patent expiration dates:
February 26, 2021 (US7153964)
April 25, 2026 (US7893074)
January 13, 2027 (US7964592)
June 29, 2030 (US8039474, US8039479)
November 20, 2027 (US8377921)
April 29, 2032 (US8703787)
Patents belong to Novartis

Definition

ChEBI: A member of the class of aminopyrimidines that is 2,6-diamino-5-chloropyrimidine in which the amino groups at positions 2 and 6 are respectively carrying 2-methoxy-4-(piperidin-4-yl)-5-methylphenyl and 2-(isopropylsulfonyl)phenyl substituents. Used for the treatment of ALK-positive metastatic non-small cell lung cancer.

1032900-25-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name Ceritinib

1.2 Other means of identification

Product number -
Other names CS-1406

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1032900-25-6 SDS

Please post your buying leads,so that our qualified suppliers will soon contact you!

*Required Fields